Intermolecular Inc (IMI) 1.14 $IMI Intermolecular to

New Post Public Reply Private Reply Replies (0) Message Board

Sep 1, 2016 at 3:02 PM

Intermolecular Inc (IMI) 1.14 $IMI

Intermolecular to Present at 2016 Flash Memory Summit on How High-Throughput Experimentation Can Identify the Most Promising Memory Selectors For 3D Cross-Point Non Volatile Memories
PR Newswire - Tue Aug 09, 11:11AM CDT
Intermolecular, Inc. (NASDAQ: IMI), the trusted partner in materials innovation, today announced it will present at the Flash Memory Summit on Thursday, August 11, 2016, at 8.30 am during the session 301-C: Intel-Micron 3D XpointTM: The Next Generation Non-Volatile Memory (New Technologies Track).
IMI: 1.14 (-0.03)

Intermolecular Announces Second Quarter 2016 Financial Results
PR Newswire - Thu Aug 04, 3:15PM CDT
Intermolecular, Inc. (NASDAQ: IMI) today reported results for its second quarter of fiscal 2016 ended June 30, 2016.
IMI: 1.14 (-0.03)

Intermolecular Appoints Chris Kramer President and CEO
PR Newswire - Thu Aug 04, 3:05PM CDT
Intermolecular, Inc. (NASDAQ: IMI), the trusted partner for advanced materials innovation, today announced that Chris Kramer has been appointed as President and Chief Executive Officer reporting to Bruce McWilliams, who will assume the role of Executive Chairman.
IMI: 1.14 (-0.03)

Intermolecular Announces First Quarter 2016 Financial Results
PR Newswire - Thu May 05, 3:25PM CDT
Intermolecular, Inc. (NASDAQ: IMI) today reported results for its first quarter of fiscal 2016 ended March 31, 2016.
IMI: 1.14 (-0.03)

ReRAM Technology Now Available Through Intermolecular's New "IMI Discoveries" Licensed Products Business
PR Newswire - Thu May 05, 8:20AM CDT
Intermolecular, Inc. (NASDAQ: IMI), the trusted partner for advanced materials innovation, today announced that its ReRAM technology is now available for licensing, marking the launch of the company's new IMI Discoveries licensed products business.
IMI: 1.14 (-0.03)

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Breaches of Fiduciary Duty by the Board of Intermolecular, Inc. - IMI
ACCESSWIRE - Wed Apr 20, 10:36AM CDT
NEW YORK, NY / ACCESSWIRE / April 20, 2016 / Levi & Korsinsky announces it has commenced an investigation of Intermolecular, Inc. (NASDAQGS: IMI) concerning possible breaches of fiduciary duty by its Board of Directors. To obtain additional information, GO TO: http://zlk.9nl.com/intermolecular-imi or contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972.
IMI: 1.14 (-0.03)

Purcell Julie & Lefkowitz LLP Is Investigating Intermolecular, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
PR Newswire - Wed Apr 20, 8:41AM CDT
Shareholder rights law firm Purcell Julie & Lefkowitz LLP has commenced an investigation of Intermolecular, Inc. (NASDAQ: IMI) concerning possible breaches of fiduciary duty by its board of directors.
IMI: 1.14 (-0.03)

Intermolecular Files Fiscal Year 2015 Financial Statements
PR Newswire - Mon Mar 28, 3:45PM CDT
Intermolecular, Inc. (NASDAQ: IMI) today filed its annual report on Form 10-K for the full year ended December 31, 2015.
IMI: 1.14 (-0.03)

Intermolecular reports 4Q loss
Automated Insights - Thu Feb 04, 5:13PM CST
SAN JOSE, Calif. (AP) _ Intermolecular Inc. (IMI) on Thursday reported a loss of $1.9 million in its fourth quarter.
IMI: 1.14 (-0.03)

Intermolecular Reports Fourth Quarter 2015 and Full Year 2015 Financial Results
PR Newswire - Thu Feb 04, 3:16PM CST
Intermolecular, Inc. (NASDAQ: IMI) today reported results for its fourth quarter and full year ended December 31, 2015.
IMI: 1.14 (-0.03)

Intermolecular to Report Fourth Quarter and Fiscal 2015 Financial Results on February 4, 2016
BusinessWire - Thu Jan 21, 3:15PM CST
Intermolecular, Inc. (NASDAQ: IMI) -- a leader in engineered materials solutions -- today announced it will release financial results for the fourth quarter and fiscal year ended December 31, 2015 after the U.S. financial markets close on Thursday, February 4, 2016. In conjunction with the release, Intermolecular will host a conference call and simultaneous audio-only webcast at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time with Bruce McWilliams, president and chief executive officer, and Rick Neely, senior vice president and chief financial officer, for Intermolecular.
IMI: 1.14 (-0.03)

Intermolecular (IMI) Jumps: Stock Adds 8% in Session
Zacks Equity Research - Zacks Investment Research - Wed Dec 30, 7:40AM CST
Intermolecular, Inc. (IMI) saw its shares rise almost 8% in the last trading session.
FN: 38.98 (+0.16), IMI: 1.14 (-0.03)

Intermolecular Announces New Developments in its Relationship With Micron
BusinessWire - Mon Nov 23, 4:33PM CST
Intermolecular, Inc. (NASDAQ:IMI) - a leader in engineered materials solutions - today announced that its Collaborative Development Program ("CDP"

agreement with Micron Technology, Inc. ("Micron"

will conclude on April 1, 2016. "Micron is a valued customer that Intermolecular hopes to serve well into the future, but the CDP model has proven too restrictive for both companies," stated Bruce McWilliams, President and CEO of Intermolecular. "Under the terms of the agreement, next April is the first opportunity for the companies to end the CDP, and last week we received Micron's notice of termination effective April 1, 2016. Until then, the companies will continue to work together under the terms of the CDP agreement, and we will seek to transition Micron's DRAM work to our new business model."
IMI: 1.14 (-0.03)

Intermolecular Announces Third Quarter 2015 Results
BusinessWire - Thu Nov 05, 3:15PM CST
Intermolecular, Inc. (NASDAQ:IMI) - a leader in engineered materials solutions - today announced results for its third quarter ended September 30, 2015
IMI: 1.14 (-0.03)

Intermolecular to Report Third Quarter 2015 Financial Results on November 5, 2015
BusinessWire - Thu Oct 15, 3:10PM CDT
Intermolecular, Inc. (NASDAQ:IMI) -- a leader in engineered materials solutions -- today announced it will release financial results for the fiscal third quarter ended September 30, 2015 after the U.S. financial markets close on Thursday, November 5, 2015. In conjunction with the release, Intermolecular will host a conference call and simultaneous audio-only webcast at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time with Bruce McWilliams, president and chief executive officer, and Rick Neely, senior vice president and chief financial officer, for Intermolecular.
IMI: 1.14 (-0.03)

Intermolecular (IMI) Catches Eye: Stock Moves 6.4% Higher
Zacks Equity Research - Zacks Investment Research - Fri Oct 09, 7:20AM CDT
Intermolecular, Inc. (IMI) was a big mover last session, as the company saw its shares rise more than 6% on the day.
NJ: 18.11 (-0.26), IMI: 1.14 (-0.03)

Intermolecular Announces Second Quarter 2015 Results
BusinessWire - Thu Aug 06, 3:18PM CDT
Intermolecular, Inc. (NASDAQ:IMI) - accelerating research and development (R&D) for advanced materials - today announced results for its second quarter ended June 30, 2015.
IMI: 1.14 (-0.03)

Intermolecular to Report Second Quarter 2015 Financial Results on August 6, 2015
BusinessWire - Thu Jul 16, 3:15PM CDT
Intermolecular, Inc. (NASDAQ:IMI)--accelerating research and development for semiconductor and clean energy industries--today announced it will release financial results for the fiscal second quarter ended June 30, 2015 after the U.S. financial markets close on Thursday, August 6, 2015. In conjunction with the release, Intermolecular will host a conference call and simultaneous audio-only webcast at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time with Bruce McWilliams, president and chief executive officer, and Rick Neely, senior vice president and chief financial officer, for Intermolecular.
IMI: 1.14 (-0.03)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Servier's Data on Tovorafenib Shows Promise in pLGG

New Light on a Critical Challenge Talk about a fight in the dark. Pediatric low-grade glioma (pLGG) is a menace that families dread, an uphill battle with odds that feel relentless. Enter Servier and its four-year updated data on OJEMDA® (tovorafenib), a beacon of hope for kids battling these tricky brain tumors. Results, presented at the SNO meeting, are fresh off the...

Novo's Research Unlocks New Insights into Food Noise

Unpacking the Science Behind Food Noise When folks think about losing weight, most picture shedding pounds and fitting into those elusive smaller jeans. But get this—there’s a curveball called ‘food noise’ that’s making waves in obesity treatment. Novo Nordisk’s semaglutide injections are shaking things up, cutting down on those persistent thoughts about food....

KINGRVER Boosts RV Comfort with New Water Heater Lineup

An Upgrade for the Open Road In the land of RV living, comfort is king—or in this case, KINGRVER. Dropping affordable upgrades for water heaters into the world of RVs, KINGRVER's CT6 lineup is like a warm hug on a chilly campsite morning. Whether you've pulled up to a wooded retreat or parked under the vast desert sky, having dependable hot water shouldn't be a gamble....

Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

YSTUDIO's Pens: A Nod to the Power of Writing

Slow Down, Write On: A New Era for Stationery In a world where sentiments zip around with a swipe, here we find YSTUDIO tapping into something analog and profound. Their latest offerings—a 'Brand Day Gift Box' and the 'Inner Universe' pen series—are more than just high-end stationery. They’re an invitation to reconnect with the written word, a gesture to slow our...

EZaccessMD Data Breach: Class Action Lawsuit Looms

Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...

SmallRig Boosts Art-Driven Innovation in AI Era

The Interplay of Art and AI In a world where the lines between man and machine blur faster than ever, creators like SmallRig are boldly asking: what role should authenticity play when AI takes the stage? The Shenzhen International Art Museum and SmallRig stood shoulder to shoulder, tackling this head-scrambling question with a global gathering of art and tech giants. It's...

Webull Faces Class Action: Key Details for Investors

What's Really Going on With Webull? When you hear there's a class-action lawsuit brewing, you know something's gone real sideways. Webull Corporation (NASDAQ: BULL) finds itself neck-deep in a securities fraud class action alleging some dicey dealings with China. If you've got skin in the game—and if you bought Webull stock between April 26, 2025, and October 6,...

WeaveGrid Powers EVConnectNC: Charging Incentives Launched

Transforming Utilities with EVConnectNC In a fresh move by WeaveGrid, North Carolina's Electric Cooperatives have teamed up to roll out EVConnectNC. This innovative program aims to manage the burgeoning demand for electric vehicle (EV) charging in rural and suburban areas under North Carolina's cooperative umbrella. Think of it as a smart way to handle new loads without...

Lilly's Obesity Breakthroughs: A Step Beyond the Scale

Pushing the Boundaries of Obesity Treatment Alright, let's cut through the noise and get to what really matters here. Eli Lilly is taking on obesity treatment like it's Clash of the Titans at this year's ObesityWeek 2026 in Washington, D.C. Forget just dropping pounds—Lilly wants to reshape how we think about obesity entirely. They're not just leaning into the scale,...